Long-term selective estrogen receptor-beta agonist treatment modulates gene expression in bone and bone marrow of ovariectomized rats

• Published in: The Journal of steroid biochemistry and molecular biology 2019-04, Vol.188, p.185-194
• Main Authors: Balla, Bernadett, Sárvári, Miklós, Kósa, János P., Kocsis-Deák, Barbara, Tobiás, Bálint, Árvai, Kristóf, Takács, István, Podani, János, Liposits, Zsolt, Lakatos, Péter
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; 17β-Estradiol; Agonists; AKT protein; Aldehyde dehydrogenase; Animals; Bone; Bone and Bones - drug effects; Bone and Bones - metabolism; Bone marrow; Bone Marrow - drug effects; Bone Marrow - metabolism; Collagen (type I); Estrogen Receptor beta - agonists; Female; Femur; Gene expression; Gene Expression Regulation - drug effects; Homeostasis; Hormones; Insulin-like growth factor I; Interleukin 6; Interleukin 6 receptors; Menopause; Nitriles - pharmacology; Notch1 protein; Ovariectomy; Propionates - pharmacology; Rat; Rats; Rats, Wistar; Selective estrogen receptor beta agonist; Signal transduction; Transcription; Transcriptome - drug effects; Transforming growth factor-b1
• ISSN: 0960-0760; 1879-1220
• DOI: 10.1016/j.jsbmb.2019.01.012

•This is the first report on bone- and bone marrow-related complex transcriptional effects of long-term selective ERβ-agonist (DPN) treatment.•DNP treatment can reverse OVX-induced expression changes of genes related to osteoblastogenesis.•Genes representing Wnt cascade show different transcriptional pattern in bone tissue after OVX or OVX completed with DPN treatment.•PI3K/Akt signaling pathways is the most affected after OVX and long-term DPN administration.•DNP treatment can compensate OVX-related transcriptional changes of genes regulating mitochondrial processes in rat femoral bone tissue. Gonadal hormones including 17β-estradiol exert important protective functions in skeletal homeostasis. However, numerous details of ovarian hormone deficiency in the common bone marrow microenvironment have not yet been revealed and little information is available on the tissue-specific acts either, especially those via estrogen receptor beta (ERβ). The aim of the present study was therefore to examine the bone-related gene expression changes after ovariectomy (OVX) and long-term ERβ agonist diarylpropionitrile (DPN) administration. We found that OVX produced strong and widespread changes of gene expression in both femoral bone and bone marrow. In the bone out of 22 genes, 20 genes were up- and 2 were downregulated after OVX. It is noteworthy that DPN restored mRNA expression of 10 OVX-induced changes (Aldh2, Col1a1, Daam1, Fgf12, Igf1, Il6r, Nfkb1, Notch1, Notch2 and Psen1) suggesting a modulatory role of ERβ in bone physiology. In bone marrow, out of 37 categorized genes, transcription of 25 genes were up- and 12 were downregulated indicating that the marrow is highly responsive to gonadal hormones. DPN modestly affected transcription, only expression of two genes (Nfatc1 and Tgfb1) was restored by DPN action. The PI3K/Akt signaling pathway was the most affected gene cluster following the interventions in bone and bone marrow, as demonstrated by canonical variates analysis (CVA). We suggested that our results contribute to a deeper understanding of alterations in gene expression of bone and bone marrow niche elicited by ERβ and selective ERβ analogs.